Apparently, a chemical in tobacco has promise of stopping dependence and fighting chronic inflammation.
In September, a Flint urologist provided a pamphlet suggesting that something in tobacco and cigarette smoke, might curtail smoking and treat auto-immune diseases, via a new drug called Anatabloc.
Rock Creek Pharmaceuticals has developed a smoking deterrent called CiGRX, which is derived from Anatabine. CiGRX is actually from two main ingredients -- yerba mate and anatabine. “Yerba Mate” is of a small tree native to South America and the average native of Uruguay consumes 2.5 to 3 gallons of Mate each year. Although, anatabine is also found in peppers, eggplant and green tomatoes -- its discovery in tobacco is a startling find.
Mark Chacon, Denver Stock Market Examiner, reported in March “Star Scientific: A struggling tobacco company sitting on a healthcare Gold Mine?” That article besides reporting on the company’s patent and trademark office [PTO] notices for two patents, added that Star “is also engaged in the development of pharmaceutical products, particularly products that have a botanical, tobacco-based component, that are designed to treat tobacco dependence and a range of neurological conditions, including Alzheimer’s disease, schizophrenia and depression, and is also in the development of non-nicotine nutraceutical products.”
In the age-old fight against aging and disease, scientist in the health and medical fields, have found that “chronic inflammation” plays a leading role in our health or the lack of it.
In 2004, Time magazine ran a special series on “Health: The Fires Within” suggesting that too much inflammation is not a good thing. But before that, in 2002, Life Extension Magazine ran an article entitled: “Chronic Inflammation The Epidemic Disease of Aging” which highlighted that [hs] high sensitivity CRP assay test measures, C Reactive Protein. “C Reactive Protein (CRP) is a blood test which could mark the body’s reaction in the liver to the signal of chronic inflammation.”
Anatabine, “received a provisional patent application to disclose whether S-(-)- anatabine is useful in reducing inflammatory activity that results in elevated blood levels of ...”